Identifying Mutations and Optimizing Use of PARP Inhibitors

Identifying Mutations and Optimizing Use of PARP Inhibitors

Cancer Center Symposium 15 May 2018Подробнее

Cancer Center Symposium 15 May 2018

Optimizing the Use of PARP Inhibitors in Ovarian CancerПодробнее

Optimizing the Use of PARP Inhibitors in Ovarian Cancer

Testing for BRCA Germline Mutations in the Clinic and the Mechanism of Action of PARP InhibitorsПодробнее

Testing for BRCA Germline Mutations in the Clinic and the Mechanism of Action of PARP Inhibitors

BRCA & PARP Inhibitors: Targeted Chemotherapy | #MarkScholzMD #AlexScholz @PCRIПодробнее

BRCA & PARP Inhibitors: Targeted Chemotherapy | #MarkScholzMD #AlexScholz @PCRI

What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science IllustratedПодробнее

What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science Illustrated

PARP Inhibitors simplifiedПодробнее

PARP Inhibitors simplified

Which mutations benefit most from PARP inhibitors in prostate cancer?Подробнее

Which mutations benefit most from PARP inhibitors in prostate cancer?

Webinar: Parp-Inhibitors and Prostate Cancer - Gotta Have a Mutation??? 06/29/2023Подробнее

Webinar: Parp-Inhibitors and Prostate Cancer - Gotta Have a Mutation??? 06/29/2023

Expanding the Benefits of PARP Inhibitors to More Patients With Breast Cancer and Earlier SettingsПодробнее

Expanding the Benefits of PARP Inhibitors to More Patients With Breast Cancer and Earlier Settings

Ovarian Cancer: How PARP Inhibitors WorkПодробнее

Ovarian Cancer: How PARP Inhibitors Work

Gynecologic Cancer Education: PARP Inhibitor TherapyПодробнее

Gynecologic Cancer Education: PARP Inhibitor Therapy

Target Practice: Understanding How PARP Inhibitors Take Aim at DDR Mutations Across Solid TumorsПодробнее

Target Practice: Understanding How PARP Inhibitors Take Aim at DDR Mutations Across Solid Tumors

Identifying optimal patient subgroups in ovarian cancer for neoadjuvant PARP inhibitor therapyПодробнее

Identifying optimal patient subgroups in ovarian cancer for neoadjuvant PARP inhibitor therapy

PARP inhibitors in metastatic breast cancer: Where are we now?Подробнее

PARP inhibitors in metastatic breast cancer: Where are we now?

ACTG Dinner Symposium Highlights | Beyond BRCA testing – does HRD matter? | Prof Michael FriedlanderПодробнее

ACTG Dinner Symposium Highlights | Beyond BRCA testing – does HRD matter? | Prof Michael Friedlander

Seminar Clips: PARP Inhibitors and BRRCA1/2 Cancers- Susan Domchek, MD | Stanford Cancer InstituteПодробнее

Seminar Clips: PARP Inhibitors and BRRCA1/2 Cancers- Susan Domchek, MD | Stanford Cancer Institute

Acting on Actionable Mutations: Genetic Testing and PARP Inhibitors for Advanced Prostate CancerПодробнее

Acting on Actionable Mutations: Genetic Testing and PARP Inhibitors for Advanced Prostate Cancer

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastati...Подробнее

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastati...

Managing metastatic breast cancer and beyond using PARP inhibitorsПодробнее

Managing metastatic breast cancer and beyond using PARP inhibitors

Актуальное